COVID-19 - Considerations for the paediatric rheumatologist

Clin Immunol. 2020 May:214:108420. doi: 10.1016/j.clim.2020.108420. Epub 2020 Apr 10.

Abstract

The novel coronavirus SARS-CoV2 is a threat to the health and well-being of millions of lifes across the globe. A significant proportion of adult patients require hospitalisation and may develop severe life-threatening complications. Children, on the other hand, can carry and transmit the virus, but usually do not develop severe disease. Mortality in the paediatric age-group is relatively low. Differences in virus containment and clearance, as well as reduced inflammation-related tissue and organ damage may be caused by age-specific environmental and host factors. Since severe complications in adults are frequently caused by uncontrolled immune responses and a resulting "cytokine storm" that may be controlled by targeted blockade of cytokines, previously established treatment with immunosuppressive treatments may indeed protect children from complications.

Keywords: ARDS; COVID; Cytokine storm; Inflammation; Paediatric; Rheumatology; SARS; SARS-CoV2.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Betacoronavirus
  • COVID-19
  • Child
  • Coinfection / virology
  • Comorbidity
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / pathology
  • Cytokines / immunology
  • Humans
  • Immune Evasion
  • Immunosuppressive Agents / administration & dosage
  • Pandemics
  • Pediatrics*
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / pathology
  • Rheumatology*
  • SARS-CoV-2

Substances

  • Cytokines
  • Immunosuppressive Agents